Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies
Titel:
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies
Auteur:
Radominski, Sebastião Cezar Cardiel, Mario Humberto Citera, Gustavo Goecke, Annelise Jaller, Juan Jose Lomonte, Andrea Barranjard Vannucci Miranda, Pedro Velez, Patricia Xibillé, Daniel Kwok, Kenneth Rojo, Ricardo García, Erika Gabriela
Verschenen in:
Reumatología clínica
Paginering:
Jaargang 13 (2017) nr. 4 pagina's 9 p.
Jaar:
2017
Inhoud:
Uitgever:
Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología